Three years after the Global Alzheimer’s Platform (GAP) Foundation launched GAP-Net, a standing network of clinical trial sites optimized for Alzheimer’s drug studies, the group convened last month in Nashville, Tennessee, to compare notes and share best practices. With 73 sites signed on, three trials currently are up and running. What have they learned? Recruitment outreach works best at the local level, but centralizing other aspects, such as IRB approval, is helpful. Standardized contracts and rater training remain sticky issues, and sites better prepare for an onslaught of newly diagnosed early stage patients expect with upcoming Medicare changes. The mostly young audience enjoyed networking with front-line workers from other trial sites. Read Pat McCaffrey’s coverage in two parts.
With three trials and initiatives to boost recruitment, GAP-Net is gaining some traction in the field.
From central IRBs, certified raters, to local transport: Changes large and small are needed to ramp up drug testing in Alzheimer’s.